Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 586-595

  Canet, Mark J ^a   Hardwick, Rhiannon N ^a   Lake, April D ^a   Dzierlenga, Anika L ^a   Clarke, John D ^a   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BREAST CANCER RESISTANCE PROTEIN; GLUCOSE; INSULIN; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1A; MULTIDRUG RESISTANCE PROTEIN 1B; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A4; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B2; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHROPOMETRIC PARAMETERS; ARTICLE; ATHEROGENIC DIET; BODY WEIGHT; CONTROLLED STUDY; DB/DB MOUSE; DIET; DISEASE ACTIVITY SCORE; DOWN REGULATION; EXPERIMENTAL ANIMAL; FA/FA RAT; GENE EXPRESSION REGULATION; GENETIC MODEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; LIVER FIBROSIS; LIVER TO BODY WEIGHT RATIO; LIVER WEIGHT; MALE; METHIONINE AND CHOLINE DEFICIENT DIET; MOUSE; MRNA EXPRESSION ASSAY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OB/OB MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; STEATOSIS; UPREGULATION; WEIGHT GAIN; WESTERN BLOTTING;

ANIMALS; CHOLINE DEFICIENCY; DIABETES MELLITUS, EXPERIMENTAL; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; FATTY LIVER; MALE; METHIONINE; MICE; MICE, INBRED C57BL; OBESITY; ORGANIC ANION TRANSPORTERS; PHARMACEUTICAL PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84896123415     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055996     Document Type: Article

References (44)

1. Ali R and Cusi K (2009) New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 41:265-278.
2. Bray GA and York DA (1979) Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev 59:719-809. (Pubitemid 9236601)
3. Canet MJ, Hardwick RN, Lake AD, Kopplin MJ, Scheffer GL, Klimecki WT, Gandolfi AJ, and Cherrington NJ (2012) Altered arsenic disposition in experimental nonalcoholic fatty liver disease. Drug Metab Dispos 40:1817-1824.
4. Carmiel-Haggai M, Cederbaum AI, and Nieto N (2005) A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 19:136-138. (Pubitemid 40069943)
5. Cherrington NJ, Estrada TE, Frisk HA, Canet MJ, Hardwick RN, Dvorak B, Lux K, and Halpern MD (2013) The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 304:G48-G56.
6. Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML, and Hayes JD (2010) Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 48:357-371.
7. Clarke JD and Cherrington NJ (2012) Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Expert Opin Drug Metab Toxicol 8:349-360.
8. Daly AK (2012) Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. Adv Pharmacol 63:137-167.
9. Feldstein AE (2010) Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 30:391-401.
10. Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, and Cherrington NJ (2008) Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol 82:959-964.
11. Fisher CD, Lickteig AJ, Augustine LM, Oude Elferink RP, Besselsen DG, Erickson RP, and Cherrington NJ (2009a) Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol 613:119-127.
12. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, and Cherrington NJ (2009b) Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37:2087-2094.
13. Hardwick RN, Fisher CD, Canet MJ, Lake AD, and Cherrington NJ (2010) Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 38:2293-2301.
14. Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, and Cherrington NJ (2011) Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos 39:2395-2402.
15. Hardwick RN, Fisher CD, Street SM, Canet MJ, and Cherrington NJ (2012) Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos 40: 450-460.
16. Hebbard L and George J (2011) Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 8:35-44.
17. Ikemura K., Nakagawa E, Kurata T, Iwamoto T, and Okuda M (2013) Altered pharmacokinetics of cimetidine caused by down-regulation of renal rat organic cation transporter 2 (rOCT2) after liver ischemia-reperfusion injury. Drug Metab Pharmacokinet 28:504-509.
18. Ingelman-Sundberg M and Rodriguez-Antona C (2005) Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 360:1563-1570.
19. Keogh JP (2012) Membrane transporters in drug development. Adv Pharmacol 63:1-42.
20. Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, and Hall PdeL (2003) Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 18:1272-1282. (Pubitemid 37464002)
21. Klaassen CD and Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1-96.
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, and Unalp-Arida A, et al.; Nonalcoholic Steatohepatitis Clinical Research Network (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321. (Pubitemid 40770284)
23. Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, and Cherrington NJ (2011) Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 39:1954-1960.
24. Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lu Z, Lehman-McKeeman LD, and Cherrington NJ (2013) Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol 268: 132-140.
25. Larter CZ and Yeh MM (2008) Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23:1635-1648.
26. Lazarou J, Pomeranz BH, and Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205. (Pubitemid 28193431)
27. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, and Robertson GR (2000) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105:1067-1075. (Pubitemid 30217691)
28. Lee AC, Dai Z, Chen B, Wu H, Wang J, Zhang A, Zhang L, Lim TM, and Lin Y (2008) Electrochemical branched-DNA assay for polymerase chain reaction-free detection and quantification of oncogenes in messenger RNA. Anal Chem 80:9402-9410.
29. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, and Cherrington NJ (2007) Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 35: 1970-1978. (Pubitemid 47481594)
30. Lomonaco R, Sunny NE, Bril F, and Cusi K (2013) Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 73:1-14.
31. Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, and Sanda MG (2009) Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology 74:1156-1161.
32. Masuoka H C and Chalasani N (2013). Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci 1281:106-122.
33. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, and Nakanuma Y, et al. (2007) Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46:1392-1403. (Pubitemid 350155521)
34. McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40 (Suppl 1):S17-S29.
35. Rinella ME and Green RM (2004) The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40:47-51. (Pubitemid 38064712)
36. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, and Whitington PF (2004) Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287:G1035-G1043. (Pubitemid 39423696)
37. Schattenberg JM and Galle PR (2010) Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis 28:247-254.
38. Shepherd G, Mohorn P, Yacoub K, and May DW (2012) Adverse drug reaction deaths reported in United States vital statistics, 1999-2006. Ann Pharmacother 46:169-175.
39. Tahan V, Yavuz D, Imeryuz N, Avsar E, and Tozun N (2004) Oral glucose tolerance deteriorates in rats fed with methionine choline deficient diet. J Hepatol 41 :352, author reply 353.
40. Takahashi Y, Soejima Y, and Fukusato T (2012) Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 18:2300-2308.
41. Valente S and Murray LP (2011) Creative strategies to improve patient safety: allergies and adverse drug reactions. J Nurses Staff Dev 27:E1-E5, quiz E6-E7.
42. Wooten JM (2010) Adverse drug reactions: Part I. South Med J 103:1025-1028, quiz 1029.
43. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, and Diehl AM (2007) Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45:1366-1374. (Pubitemid 46918320)
44. Yiannakopoulou ECh (2013) Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications. Pharmacogenomics J 13:105-109.